Clinical trial · Observational
The Implication of ctDNA in the Recurrence Surveillance of Stage II and III Colorectal Cancer
The Implication of Plasma Circulating Tumor DNA (ctDNA) in the Recurrence Surveillance of Stage II and III Colorectal Cancer: a Prospective Study
NCT03416478CI-TRIAL-00031480unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is to evaluate circulating tumor DNA (ctDNA) as a predictive and surveillant method for tumor recurrence in stage II and III colorectal cancer (CRC).
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| ctDNA | — | UNRESOLVED | — |
| Surveillance | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ctDNA test | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- ctDNA test group
- interventionNames
- Diagnostic Test: ctDNA test
Primary outcomes (1)
- measure
- Disease Free Survival
- timeFrame
- Two years
Secondary outcomes (1)
- measure
- Overall survival
- timeFrame
- Two years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Male or female ≥ 18 years of age on the day of signing informed consent. * Patients must have histologically confirmed stage II or IIIcolorectal cancer. * Patients must receive radical resection. * Written informed consent must be obtained from patient or patient's legal representative and ability for patient to comply with the requirements of the study. Exclusion Criteria: * Patient has severe anemia. * Patients received neoadjuvant treatment. * Patients received blood transfusion two weeks before or during the surgical resection. * Patient has any other conditions, which, in the opinion of the Investigator, would interfere with the evaluation of the subject
References
Publications (0)
Data not yet available
No reference posted for this study.